$3.26
1.56% day before yesterday
Nasdaq, Dec 24, 07:04 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$3.26
-0.06 1.81% 1M
+2.53 349.16% 6M
-1.17 26.41% YTD
-1.35 29.28% 1Y
-9.12 73.67% 3Y
-8.46 72.18% 5Y
-6.45 66.42% 10Y
-6.49 66.57% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.05 1.56%

Key metrics

Basic
Market capitalization
$530.3m
Enterprise Value
$974.4m
Net debt
$444.1m
Cash
$140.4m
Shares outstanding
162.7m
Valuation (TTM | estimate)
P/E
20.4 | 10.8
P/S
1.6 | 1.7
EV/Sales
2.9 | 3.1
EV/FCF
14.4
P/B
negative
Financial Health
Equity Ratio
-85.9%
Return on Equity
-0.3%
ROCE
93.6%
ROIC
17.4%
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$339.0m | $313.2m
EBITDA
$145.6m | $153.3m
EBIT
$143.7m | $113.4m
Net Income
$28.6m | $49.0m
Free Cash Flow
$67.7m
Growth (TTM | estimate)
Revenue
-10.4% | -10.9%
EBITDA
33.1% | 56.8%
EBIT
33.8% | 18.5%
Net Income
1,260.6% | 5,462.5%
Free Cash Flow
-43.6%
Margin (TTM | estimate)
Gross
-
EBITDA
42.9% | 48.9%
EBIT
42.4%
Net
8.4% | 15.6%
Free Cash Flow
20.0%
More
EPS
$0.2
FCF per Share
$0.4
Short interest
7.0%
Employees
253
Rev per Employee
$1.4m
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Ironwood Pharmaceuticals forecast:

6x Hold
67%
3x Sell
33%

Analyst Opinions

9 Analysts have issued a Ironwood Pharmaceuticals forecast:

Hold
67%
Sell
33%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
339 339
10% 10%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 97 97
35% 35%
29%
- Research and Development Expense 99 99
19% 19%
29%
146 146
33% 33%
43%
- Depreciation and Amortization 1.91 1.91
6% 6%
1%
EBIT (Operating Income) EBIT 144 144
34% 34%
42%
Net Profit 29 29
1,261% 1,261%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Positive
Seeking Alpha
29 days ago
Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% yea...
Neutral
Business Wire
about 2 months ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription ...
Neutral
Accesswire
2 months ago
CALGARY, AB / ACCESS Newswire / October 24, 2025 / Ironwood Stair & Rail Inc., a company built on craftsmanship and passion, has been recognised with the 2025 Consumer Choice Award in the Stairs and Railings category for Southern Alberta. This recognition highlights Ironwood's reputation for exceptional design, quality, and service in transforming homes and businesses with custom-built stairs a...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 253
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today